135 related articles for article (PubMed ID: 33357097)
21. Screening for RAD51 and BRCA2 BRC repeat mutations in breast and ovarian cancer families.
Rapakko K; Heikkinen K; Karppinen SM; Winqvist R
Cancer Lett; 2006 May; 236(1):142-7. PubMed ID: 16005565
[TBL] [Abstract][Full Text] [Related]
22. A phosphorylation-deubiquitination cascade regulates the BRCA2-RAD51 axis in homologous recombination.
Luo K; Li L; Li Y; Wu C; Yin Y; Chen Y; Deng M; Nowsheen S; Yuan J; Lou Z
Genes Dev; 2016 Dec; 30(23):2581-2595. PubMed ID: 27941124
[TBL] [Abstract][Full Text] [Related]
23. BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
Tsibulak I; Wieser V; Degasper C; Shivalingaiah G; Wenzel S; Sprung S; Lax SF; Marth C; Fiegl H; Zeimet AG
Br J Cancer; 2018 Sep; 119(6):683-692. PubMed ID: 30111871
[TBL] [Abstract][Full Text] [Related]
24. Phenotypic effects of heterozygosity for a BRCA2 mutation.
Warren M; Lord CJ; Masabanda J; Griffin D; Ashworth A
Hum Mol Genet; 2003 Oct; 12(20):2645-56. PubMed ID: 12928478
[TBL] [Abstract][Full Text] [Related]
25. Fanconi anemia complementation group D2 (FANCD2) functions independently of BRCA2- and RAD51-associated homologous recombination in response to DNA damage.
Ohashi A; Zdzienicka MZ; Chen J; Couch FJ
J Biol Chem; 2005 Apr; 280(15):14877-83. PubMed ID: 15671039
[TBL] [Abstract][Full Text] [Related]
26. Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines.
Kwon WS; Rha SY; Jeung HC; Kim TS; Chung HC
Biochem Pharmacol; 2017 Aug; 138():163-173. PubMed ID: 28431939
[TBL] [Abstract][Full Text] [Related]
27. The epistatic relationship between BRCA2 and the other RAD51 mediators in homologous recombination.
Qing Y; Yamazoe M; Hirota K; Dejsuphong D; Sakai W; Yamamoto KN; Bishop DK; Wu X; Takeda S
PLoS Genet; 2011 Jul; 7(7):e1002148. PubMed ID: 21779174
[TBL] [Abstract][Full Text] [Related]
28. BRCA2 keeps Rad51 in line. High-fidelity homologous recombination prevents breast and ovarian cancer?
Powell SN; Willers H; Xia F
Mol Cell; 2002 Dec; 10(6):1262-3. PubMed ID: 12504001
[TBL] [Abstract][Full Text] [Related]
29. Arabidopsis BRCA2 and RAD51 proteins are specifically involved in defense gene transcription during plant immune responses.
Wang S; Durrant WE; Song J; Spivey NW; Dong X
Proc Natl Acad Sci U S A; 2010 Dec; 107(52):22716-21. PubMed ID: 21149701
[TBL] [Abstract][Full Text] [Related]
30. EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases.
Cousineau I; Belmaaza A
Mol Genet Genomics; 2011 Apr; 285(4):325-40. PubMed ID: 21409565
[TBL] [Abstract][Full Text] [Related]
31. BRCA2: a universal recombinase regulator.
Thorslund T; West SC
Oncogene; 2007 Dec; 26(56):7720-30. PubMed ID: 18066084
[TBL] [Abstract][Full Text] [Related]
32. Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells.
Roberti M; Schipani F; Bagnolini G; Milano D; Giacomini E; Falchi F; Balboni A; Manerba M; Farabegoli F; De Franco F; Robertson J; Minucci S; Pallavicini I; Di Stefano G; Girotto S; Pellicciari R; Cavalli A
Eur J Med Chem; 2019 Mar; 165():80-92. PubMed ID: 30660828
[TBL] [Abstract][Full Text] [Related]
33. A new assay for functional screening of BRCA2 linker region mutations identifies variants that alter chemoresistance to cisplatin.
Warren CR; Catts ZA; Farach-Carson MC
Exp Cell Res; 2011 Sep; 317(15):2099-109. PubMed ID: 21741379
[TBL] [Abstract][Full Text] [Related]
34. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
Du P; Zhang X; Liu H; Chen L
DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
[TBL] [Abstract][Full Text] [Related]
35. A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
Tumiati M; Hietanen S; Hynninen J; Pietilä E; Färkkilä A; Kaipio K; Roering P; Huhtinen K; Alkodsi A; Li Y; Lehtonen R; Erkan EP; Tuominen MM; Lehti K; Hautaniemi SK; Vähärautio A; Grénman S; Carpén O; Kauppi L
Clin Cancer Res; 2018 Sep; 24(18):4482-4493. PubMed ID: 29858219
[No Abstract] [Full Text] [Related]
36. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
Waks AG; Cohen O; Kochupurakkal B; Kim D; Dunn CE; Buendia Buendia J; Wander S; Helvie K; Lloyd MR; Marini L; Hughes ME; Freeman SS; Ivy SP; Geradts J; Isakoff S; LoRusso P; Adalsteinsson VA; Tolaney SM; Matulonis U; Krop IE; D'Andrea AD; Winer EP; Lin NU; Shapiro GI; Wagle N
Ann Oncol; 2020 May; 31(5):590-598. PubMed ID: 32245699
[TBL] [Abstract][Full Text] [Related]
37. 53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.
Pennington KP; Wickramanayake A; Norquist BM; Pennil CC; Garcia RL; Agnew KJ; Taniguchi T; Welcsh P; Swisher EM
Gynecol Oncol; 2013 Mar; 128(3):493-9. PubMed ID: 23246380
[TBL] [Abstract][Full Text] [Related]
38. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers.
Rebbeck TR; Mitra N; Domchek SM; Wan F; Chuai S; Friebel TM; Panossian S; Spurdle A; Chenevix-Trench G; ; Singer CF; Pfeiler G; Neuhausen SL; Lynch HT; Garber JE; Weitzel JN; Isaacs C; Couch F; Narod SA; Rubinstein WS; Tomlinson GE; Ganz PA; Olopade OI; Tung N; Blum JL; Greenberg R; Nathanson KL; Daly MB
Cancer Res; 2009 Jul; 69(14):5801-10. PubMed ID: 19584272
[TBL] [Abstract][Full Text] [Related]
39. Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas.
Moes-Sosnowska J; Rzepecka IK; Chodzynska J; Dansonka-Mieszkowska A; Szafron LM; Balabas A; Lotocka R; Sobiczewski P; Kupryjanczyk J
Cancer Biol Ther; 2019; 20(6):843-854. PubMed ID: 30822218
[TBL] [Abstract][Full Text] [Related]
40. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.
Wang WW; Spurdle AB; Kolachana P; Bove B; Modan B; Ebbers SM; Suthers G; Tucker MA; Kaufman DJ; Doody MM; Tarone RE; Daly M; Levavi H; Pierce H; Chetrit A; Yechezkel GH; Chenevix-Trench G; Offit K; Godwin AK; Struewing JP
Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):955-60. PubMed ID: 11535547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
